RIBOMIC has signed the license agreement with AJU PHARM CO., LTD., Korean pharmaceutical company (“AJU”), for RBM-007 licensing agreement for the indication of the exudative age-related macular degeneration in the territory of Korea and Southeast Asia (Singapore, Philippines, Thailand, Vietnam, Indonesia, Malaysia, Cambodia and Myanmar; hereinafter "the Territory").
Pfizer has collaborated with Biopharmaceutical New Technologies (BioNTech) for the co-development of a potential COVID-19 vaccine.
AcelRx Pharmaceuticals, a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced the execution of a definitive merger agreement to acquire Tetraphase Pharmaceuticals, Inc. (Tetraphase) in a stock for stock deal at an exchange ratio of 0.6303 shares of AcelRx for each share of Tetraphase, or approximately $14.4 million as of the close of trading on March 13, 2020, plus a contingent value right (CVR).
BioStem Life Sciences, a wholly owned subsidiary of BioStem Technologies, Inc. (OTC PINK: BSEM) ("BioStem" or the "Company") a leading life sciences company specializing in perinatal tissue-based allografts for use in regenerative therapies, today announced the buildout of a brand new R&D lab.
Can-Fite BioPharma, a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, is entering into a collaborative research agreement with the Lewis Katz School of Medicine at Temple University, Philadelphia, USA.
Forty Seven and Rocket Pharmaceuticals have entered into a research collaboration for evaluating a new treatment regimen in Fanconi Anemia, a rare paediatric disease.
Silverback Therapeutics (“Silverback”) (“the Company”), a private biopharmaceutical company pioneering a new class of immune-modulating ImmunoTAC drug conjugates targeting previously inaccessible disease pathways, today announced the close of an oversubscribed $78.5 million Series B financing round.
Brii Biosciences (“Brii Bio”) and Columbia University have entered into a memorandum of understanding through which Brii Bio will provide funding to support research to be conducted by investigators at the university and led by David Ho, M.D., founding scientific director of the Aaron Diamond AIDS Research Center and professor of medicine at the Vagelos College of Physicians and Surgeons.
Kuur Therapeutics announced the launch of its new business in partnership with Baylor College of Medicine and Baylor’s Center for Cell and Gene Therapy. Houston-based Kuur Therapeutics will advance the work of its predecessor, Cell Medica, to develop anti-cancer therapies using its innovative chimeric antigen receptor natural killer T cell (CAR-NKT) therapy platform.
Mount Sinai Health System and Harbour BioMed (HBM) have entered into a multi-year, multifaceted collaboration to develop novel, fully human antibodies for the treatment and prevention of various diseases including oncology and immunology.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.